AAPL335.08-1.92 (-0.57%) ▼|ABBV263.93-0.09 (-0.03%) ▼|ABT102.85+0.62 (+0.61%) ▲|ACN182.51-7.79 (-4.09%) ▼|ADBE249.66-3.01 (-1.19%) ▼|AMAT435.03+17.63 (+4.22%) ▲|AMD546.25+1.16 (+0.21%) ▲|AMGN383.43+3.65 (+0.96%) ▲|AMT175.02-0.57 (-0.32%) ▼|AMZN253.09+1.90 (+0.76%) ▲|AVGO354.55+7.25 (+2.09%) ▲|AXP311.56+0.39 (+0.13%) ▲|BA197.41+0.41 (+0.21%) ▲|BAC57.75-0.44 (-0.75%) ▼|BKNG168.22-2.30 (-1.35%) ▼|BLK1,059.34+5.38 (+0.51%) ▲|BMY62.64-0.20 (-0.32%) ▼|BNY152.81-0.21 (-0.14%) ▼|BRK-B508.80-0.40 (-0.08%) ▼|C131.97-0.73 (-0.55%) ▼|CAT800.52+1.95 (+0.24%) ▲|CL87.35-0.39 (-0.44%) ▼|CMCSA22.76-0.16 (-0.68%) ▼|COF201.95-0.09 (-0.04%) ▼|COP132.01-1.18 (-0.89%) ▼|COST895.09+1.16 (+0.13%) ▲|CRM238.60-4.25 (-1.75%) ▼|CSCO108.88-1.37 (-1.24%) ▼|CVS88.38-1.89 (-2.09%) ▼|CVX210.81-0.76 (-0.36%) ▼|DE680.86-4.77 (-0.70%) ▼|DHR210.88-1.62 (-0.76%) ▼|DIS102.89-2.46 (-2.34%) ▼|DUK117.45-1.10 (-0.92%) ▼|EMR148.72+1.32 (+0.90%) ▲|FDX302.48-3.40 (-1.11%) ▼|GD351.75-4.20 (-1.18%) ▼|GE312.59-0.89 (-0.28%) ▼|GEV930.01+5.08 (+0.55%) ▲|GILD150.86-0.03 (-0.02%) ▼|GM81.93-4.69 (-5.41%) ▼|GOOG345.69+2.01 (+0.58%) ▲|GOOGL349.57+2.24 (+0.64%) ▲|GS944.95-6.52 (-0.68%) ▼|HD300.14-2.37 (-0.78%) ▼|HON204.94-1.55 (-0.75%) ▼|IBM230.34-7.42 (-3.12%) ▼|INTC107.15-1.66 (-1.52%) ▼|INTU301.10-12.04 (-3.84%) ▼|ISRG392.38+8.84 (+2.30%) ▲|JNJ270.34+0.12 (+0.04%) ▲|JPM346.97-2.35 (-0.67%) ▼|KO87.85-0.22 (-0.24%) ▼|LIN459.15+0.67 (+0.15%) ▲|LLY1,145.33-7.11 (-0.62%) ▼|LMT531.22-6.87 (-1.28%) ▼|LOW192.39-1.80 (-0.93%) ▼|LRCX282.33+13.02 (+4.84%) ▲|MA565.34-0.39 (-0.07%) ▼|MCD249.10+0.62 (+0.25%) ▲|MDLZ60.83-1.21 (-1.95%) ▼|MDT92.47-0.30 (-0.32%) ▼|META671.43-10.88 (-1.59%) ▼|MMM164.98+0.27 (+0.17%) ▲|MO69.72+0.02 (+0.02%) ▲|MRK146.09-1.06 (-0.72%) ▼|MS202.14-1.38 (-0.68%) ▼|MSFT495.27-2.48 (-0.50%) ▼|MU998.60+21.10 (+2.16%) ▲|NEE80.60-0.69 (-0.84%) ▼|NFLX71.82-3.49 (-4.63%) ▼|NKE35.82-0.54 (-1.49%) ▼|NOW136.95-1.52 (-1.10%) ▼|NVDA219.81+0.47 (+0.21%) ▲|ORCL146.31-4.28 (-2.84%) ▼|PEP130.42-3.24 (-2.42%) ▼|PFE27.53-0.12 (-0.42%) ▼|PG146.33-1.23 (-0.83%) ▼|PLTR175.85-0.39 (-0.22%) ▼|PM189.67-0.81 (-0.43%) ▼|QCOM178.40-10.32 (-5.47%) ▼|RTX192.19-1.35 (-0.70%) ▼|SBUX95.34-1.33 (-1.38%) ▼|SCHW104.89+0.26 (+0.25%) ▲|SO85.71-1.05 (-1.21%) ▼|SPG204.16-0.31 (-0.15%) ▼|T25.53+0.14 (+0.55%) ▲|TMO650.03-8.29 (-1.26%) ▼|TMUS167.57+1.12 (+0.67%) ▲|TSLA362.97-3.24 (-0.88%) ▼|TXN263.10+4.96 (+1.92%) ▲|UBER70.46-0.41 (-0.58%) ▼|UNH374.28-0.94 (-0.25%) ▼|UNP279.70-2.78 (-0.98%) ▼|UPS98.93-1.25 (-1.24%) ▼|USB59.92-0.34 (-0.56%) ▼|V369.03-0.90 (-0.24%) ▼|VZ48.10-0.23 (-0.48%) ▼|WFC86.15-0.75 (-0.86%) ▼|WMT107.24+0.45 (+0.42%) ▲|XOM162.80-0.47 (-0.29%) ▼|AAPL335.08-1.92 (-0.57%) ▼|ABBV263.93-0.09 (-0.03%) ▼|ABT102.85+0.62 (+0.61%) ▲|ACN182.51-7.79 (-4.09%) ▼|ADBE249.66-3.01 (-1.19%) ▼|AMAT435.03+17.63 (+4.22%) ▲|AMD546.25+1.16 (+0.21%) ▲|AMGN383.43+3.65 (+0.96%) ▲|AMT175.02-0.57 (-0.32%) ▼|AMZN253.09+1.90 (+0.76%) ▲|AVGO354.55+7.25 (+2.09%) ▲|AXP311.56+0.39 (+0.13%) ▲|BA197.41+0.41 (+0.21%) ▲|BAC57.75-0.44 (-0.75%) ▼|BKNG168.22-2.30 (-1.35%) ▼|BLK1,059.34+5.38 (+0.51%) ▲|BMY62.64-0.20 (-0.32%) ▼|BNY152.81-0.21 (-0.14%) ▼|BRK-B508.80-0.40 (-0.08%) ▼|C131.97-0.73 (-0.55%) ▼|CAT800.52+1.95 (+0.24%) ▲|CL87.35-0.39 (-0.44%) ▼|CMCSA22.76-0.16 (-0.68%) ▼|COF201.95-0.09 (-0.04%) ▼|COP132.01-1.18 (-0.89%) ▼|COST895.09+1.16 (+0.13%) ▲|CRM238.60-4.25 (-1.75%) ▼|CSCO108.88-1.37 (-1.24%) ▼|CVS88.38-1.89 (-2.09%) ▼|CVX210.81-0.76 (-0.36%) ▼|DE680.86-4.77 (-0.70%) ▼|DHR210.88-1.62 (-0.76%) ▼|DIS102.89-2.46 (-2.34%) ▼|DUK117.45-1.10 (-0.92%) ▼|EMR148.72+1.32 (+0.90%) ▲|FDX302.48-3.40 (-1.11%) ▼|GD351.75-4.20 (-1.18%) ▼|GE312.59-0.89 (-0.28%) ▼|GEV930.01+5.08 (+0.55%) ▲|GILD150.86-0.03 (-0.02%) ▼|GM81.93-4.69 (-5.41%) ▼|GOOG345.69+2.01 (+0.58%) ▲|GOOGL349.57+2.24 (+0.64%) ▲|GS944.95-6.52 (-0.68%) ▼|HD300.14-2.37 (-0.78%) ▼|HON204.94-1.55 (-0.75%) ▼|IBM230.34-7.42 (-3.12%) ▼|INTC107.15-1.66 (-1.52%) ▼|INTU301.10-12.04 (-3.84%) ▼|ISRG392.38+8.84 (+2.30%) ▲|JNJ270.34+0.12 (+0.04%) ▲|JPM346.97-2.35 (-0.67%) ▼|KO87.85-0.22 (-0.24%) ▼|LIN459.15+0.67 (+0.15%) ▲|LLY1,145.33-7.11 (-0.62%) ▼|LMT531.22-6.87 (-1.28%) ▼|LOW192.39-1.80 (-0.93%) ▼|LRCX282.33+13.02 (+4.84%) ▲|MA565.34-0.39 (-0.07%) ▼|MCD249.10+0.62 (+0.25%) ▲|MDLZ60.83-1.21 (-1.95%) ▼|MDT92.47-0.30 (-0.32%) ▼|META671.43-10.88 (-1.59%) ▼|MMM164.98+0.27 (+0.17%) ▲|MO69.72+0.02 (+0.02%) ▲|MRK146.09-1.06 (-0.72%) ▼|MS202.14-1.38 (-0.68%) ▼|MSFT495.27-2.48 (-0.50%) ▼|MU998.60+21.10 (+2.16%) ▲|NEE80.60-0.69 (-0.84%) ▼|NFLX71.82-3.49 (-4.63%) ▼|NKE35.82-0.54 (-1.49%) ▼|NOW136.95-1.52 (-1.10%) ▼|NVDA219.81+0.47 (+0.21%) ▲|ORCL146.31-4.28 (-2.84%) ▼|PEP130.42-3.24 (-2.42%) ▼|PFE27.53-0.12 (-0.42%) ▼|PG146.33-1.23 (-0.83%) ▼|PLTR175.85-0.39 (-0.22%) ▼|PM189.67-0.81 (-0.43%) ▼|QCOM178.40-10.32 (-5.47%) ▼|RTX192.19-1.35 (-0.70%) ▼|SBUX95.34-1.33 (-1.38%) ▼|SCHW104.89+0.26 (+0.25%) ▲|SO85.71-1.05 (-1.21%) ▼|SPG204.16-0.31 (-0.15%) ▼|T25.53+0.14 (+0.55%) ▲|TMO650.03-8.29 (-1.26%) ▼|TMUS167.57+1.12 (+0.67%) ▲|TSLA362.97-3.24 (-0.88%) ▼|TXN263.10+4.96 (+1.92%) ▲|UBER70.46-0.41 (-0.58%) ▼|UNH374.28-0.94 (-0.25%) ▼|UNP279.70-2.78 (-0.98%) ▼|UPS98.93-1.25 (-1.24%) ▼|USB59.92-0.34 (-0.56%) ▼|V369.03-0.90 (-0.24%) ▼|VZ48.10-0.23 (-0.48%) ▼|WFC86.15-0.75 (-0.86%) ▼|WMT107.24+0.45 (+0.42%) ▲|XOM162.80-0.47 (-0.29%) ▼|
28 C
New York
Friday, September 18, 2026

Tag: programs

newssourceFORcompanyinformationcontent1releasesmarket

Finlay Minerals announces the commencement of the 2025 PIL & ATTY Property Exploration Programs

VANCOUVER, BC, June 18, 2025 /CNW/ - Finlay Minerals Ltd. (TSXV: FYL) (OTCQB: FYMNF) ("Finlay" or the "Company") is pleased to announce the start...

Drilling Underway at Northern Shield’s Root & Cellar Property Targeting Epithermal Gold-Tellurium-Silver Mineralization

OTTAWA, ON, June 18, 2025 /CNW/ - Northern Shield Resources Inc. ("Northern Shield" or the "Company") is pleased to announce that diamond drilling has...

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 to <16. Both non-ambulatory and ambulatory participants may qualify for the study. Participants will be randomized 2:1 to receive omaveloxolone or placebo once a day for 52 weeks before having the opportunity to move into the open-label extension (OLE). Currently, omaveloxolone is commercialized under the brand name SKYCLARYS® in over 40 countries, including in the U.S. and the European Union, and is the only approved product for FA in adults and adolescents aged 16 years and older.

Remepy’s Mobile App Shown to Rewire Brain, Modulate Immune System and Improve Mood in Adults with Subjective Cognitive Decline

RMPY-008 is the first app-based intervention to demonstrate rapid modulation of inflammatory blood biomarkers, acting like a digital antibody in just three weeks Finding from...

School’s Out, Pens Down: Staples Canada offers free recycling for used writing tools

More than 10 million writing instruments have been diverted from landfills through Staples Canada's partnership with TerraCycle RICHMOND HILL, ON, June 18, 2025 /CNW/ - As...

Special Education School Celebrates Graduation

LOS ANGELES, June 18, 2025 /PRNewswire/ -- Wayfinder Family Services' Special Education School, a state-certified non-public school, recently celebrated its graduating class with a ceremony and...

House Policy Bill: Debt Tsunami Drowns Economic “Gains” in Fiscal Fantasyland

In the latest episode of "Let's Pretend We Understand Fiscal Responsibility," the Congressional Budget Office (CBO) has delivered yet another scathing assessment of the...

KC Global Media Welcomes TPBL Star Kenny Chien as First Active Player to Commentate League Finals

SINGAPORE, KUALA LUMPUR, Malaysia and TAIPEI, June 18, 2025 /PRNewswire/ -- KC Global Media is proud to announce that Kenny Chien, guard, Taipei Taishin...

Rewind Therapeutics Strengthens Scientific Advisory Board with Leading International Neurology Experts as it Advances First-in-Class Remyelination Therapy

Professors Shiv Saidha, Cristina Granziera, David Leppert, and Roberto Furlan are world-renowned experts in neuroimaging, multiple sclerosis (MS) biomarkers, neuroimmunology, and translational drug developmentAppointments...

4 Generations Are Persevering Against Headwinds and Uncertainties to Prepare for Retirement

New report examines the tenuous prospects of Gen Z, Millennial, Gen X, and Baby Boomer workers LOS ANGELES, June 18, 2025 /PRNewswire/ -- Eight in...

FDH Aero Signs Expanded Agreement with Gardner Aerospace

Partnership will leverage Just-in-Time services to enhance Airbus programs in India 
Partnership will leverage Just-in-Time services to enhance Airbus programs in India

Toledo Zoo’s Expertise Helps Hatch Chicks of One of the World’s Rarest Birds

Three blue-eyed ground dove chicks mark a major milestone in international conservation effort guided in part by the Toledo Zoo TOLEDO, Ohio, June 18, 2025...

ZERO Prostate Cancer and Tolmar Launch Groundbreaking “Peaks Challenge” to Spotlight Survivorship and Early Detection

9 Survivors. 11 Advocates. One Mountain. A Life-Changing Mission to Save Lives. ALEXANDRIA, Va., June 17, 2025 /PRNewswire/ -- ZERO Prostate Cancer, the nation's leading...

Schools of Nursing See Enrollment Increases Across Most Program Levels, Signaling Strong Interest in Nursing Careers

PhD Nursing Programs See 11th Year of Enrollment Declines WASHINGTON, June 17, 2025 /PRNewswire/ -- New data released today by the American Association of Colleges...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPrograms

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers